{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:48:24Z","timestamp":1788778104456,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1692-y","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T07:32:15Z","timestamp":1470382335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital"],"prefix":"10.1186","volume":"16","author":[{"given":"Muneyoshi","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Araoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hishinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"issue":"4","key":"1692_CR1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious disease society of America. Clin Infect Dis. 2011;52(4):427\u201331.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1692_CR2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/bmt.2009.216","volume":"45","author":"KA Guthrie","year":"2010","unstructured":"Guthrie KA, Yong M, Frieze D, Corey L, Fredricks DN. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(4):675\u201381.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1692_CR3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1399-3062.2011.00650.x","volume":"14","author":"A Busca","year":"2012","unstructured":"Busca A, Cavecchia I, Locatelli F, D\u2019Ardia S, De Rosa FG, Marmont F, et al. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012;14(1):40\u20138.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"1692_CR4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/tid.12175","volume":"16","author":"O Blennow","year":"2014","unstructured":"Blennow O, Liunqman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of blood stream infections during the pre-engraftment phase in 512 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16(1):106\u201314.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"1692_CR5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jinf.2014.06.004","volume":"69","author":"SK Seo","year":"2014","unstructured":"Seo SK, Xiao K, Haung YT, Jongwutiwes U, Chung D, Maloy M, et al. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution study. J Infect. 2014;69(4):341\u201351.","journal-title":"J Infect"},{"issue":"11","key":"1692_CR6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1086\/340352","volume":"34","author":"RR Razonable","year":"2002","unstructured":"Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis. 2002;34(11):1469\u201374.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1692_CR7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0002-9343(94)90009-4","volume":"97","author":"PY Bochud","year":"1994","unstructured":"Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. American J Med. 1994;97(3):256\u201364.","journal-title":"American J Med"},{"issue":"7","key":"1692_CR8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.2004.09.108","volume":"22","author":"A Gassas","year":"2004","unstructured":"Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem cell transplant recipients. J Clin Oncol. 2004;22(7):1222\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1692_CR9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/clinids\/14.6.1201","volume":"14","author":"L Elting","year":"1992","unstructured":"Elting L, Bodey GP, Keefe BH. Septicemia and septic shock syndrome due to viridans streptococci: a case\u2013control study of predisposing factors. Clin Infect Dis. 1992;14(6):1201\u20137.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1692_CR10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/317460","volume":"31","author":"A Marron","year":"2000","unstructured":"Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000;31(5):1126\u201330.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1692_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu260","volume":"59","author":"SA Shelburne 3rd","year":"2014","unstructured":"Shelburne 3rd SA, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV. Development and validation of a clinical model to predict the presence of \u03b2-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis. 2014;59(2):223\u201330.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1692_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1701057","volume":"21","author":"C Arms da Cunha","year":"1998","unstructured":"Arms da Cunha C, Weisdorf D, Shu XO, DeFor T, Pastor 3rd JD, Jhonson JR. Early gram-positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant. 1998;21(2):173\u201380.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"1692_CR13","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1086\/425612","volume":"39","author":"D Jaffe","year":"2004","unstructured":"Jaffe D, Jakubowski A, Sepkowitz K, Sebti R, Kiehn TE, Pamer E, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis. 2004;39(11):1625\u201332.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1692_CR14","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/383054","volume":"15","author":"T Masaoka","year":"2004","unstructured":"Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: Executive Summary. Clin Infect Dis. 2004;15 Suppl 1:S49\u201352.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1692_CR15","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.bbmt.2014.06.024","volume":"20","author":"H Yamamoto","year":"2014","unstructured":"Yamamoto H, Uchida N, Matsuno N, Ota H, Kageyama K, Wada S, et al. Anti-HLA antibodies other than against HLA-A, B, DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. Biol Blood Marrow Transplant. 2014;20(10):1634\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1692_CR16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giral","year":"2009","unstructured":"Giral S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1692_CR17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","volume":"41","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580\u2013637.","journal-title":"Crit Care Med"},{"issue":"23","key":"1692_CR18","first-page":"2526","volume":"307","author":"ARDS Definition Task Force","year":"2012","unstructured":"Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526\u201333.","journal-title":"JAMA"},{"issue":"12","key":"1692_CR19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Revised difinitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infectious Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1692_CR20","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1128\/JCM.43.12.6073-6085.2005","volume":"43","author":"T Hoshino","year":"2005","unstructured":"Hoshino T, Fujiwara T, Kilian M. Use of phylogenetic and phenotypic analyses to identify nonhemolytic streptococci isolated from bacteremic patients. J Clin Microbiol. 2005;43(12):6073\u201385.","journal-title":"J Clin Microbiol"},{"key":"1692_CR21","volume-title":"Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement","author":"Clinical and Laboratory Standard Institute","year":"2012","unstructured":"Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement. Wayne: Document M100-S22 CLSI; 2012."},{"issue":"3","key":"1692_CR22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available east-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"6\u20137","key":"1692_CR23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/00365540601131950","volume":"39","author":"M Lindgren","year":"2007","unstructured":"Lindgren M, Jalava J, Rantakokko-Jalava K, Meurman O. In vitro susceptibility of viridans group streptococci isolated from blood in southwest Finland in 1993\u20132004. Scand J Infect Dis. 2007;39(6\u20137):508\u201313.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"1692_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MPH.0b013e31819a5d40","volume":"31","author":"S Paulus","year":"2009","unstructured":"Paulus S, Dobson S, Rassekh S, Blondel-Hill E. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotics choices. J Pediatr Hematol Oncol. 2009;31(4):267\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"1692_CR25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/47.1.87","volume":"47","author":"A Marron","year":"2001","unstructured":"Marron A, Carratala J, Alcaide F, Fernandez-Sevilla A, Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteremia in neutropenic cancer patients. J Antimicrob Chemother. 2001;47(1):87\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1692_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1399-3062.2005.00088.x","volume":"7","author":"NG Almyroudis","year":"2005","unstructured":"Almyroudis NG, Fuller A, Jakubowski A. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7(1):11\u20137.","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"1692_CR27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3201\/eid2005.130953","volume":"20","author":"SA Shelburn","year":"2014","unstructured":"Shelburn SA, Sahasrabhojane P, Saldana M, Yao H, Su X, Horstmann N, et al. Streptococcus mitis strains causing severe clinical diseases in cancer patients. Emerg Infect Dis. 2014;20(5):762\u201371.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"1692_CR28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977\u201387.","journal-title":"N Engl J Med"},{"issue":"12 Pt 1","key":"1692_CR29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","volume":"142","author":"A Gafter-Gvili","year":"2005","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12 Pt 1):979\u201395.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1692_CR30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-005-1278-x","volume":"24","author":"WV Kern","year":"2005","unstructured":"Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution effects of discontinuing prophylactic fluoroquinolone use in neutropenoic patients with leukemia. Eur J Clin microbial Infect Dis. 2005;24(2):111\u20138.","journal-title":"Eur J Clin microbial Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1692-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:02:38Z","timestamp":1498320158000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1692-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1692-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"article-number":"372"}}